MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro

Autoimmunity

Volumn 46, Issue 6, 2013, Pages 351-362

  Chafin, Cristen B ^a   Regna, Nicole L ^a   Dai, Rujuan ^a   Caudell, David L ^a   Reilly, Christopher M ^a,b  

^a CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

^b EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Immune stimulation; Inflammatory mediators; Mesangial cells; MicroRNAs; Systemic lupus erythematosus

Indexed keywords

DACTINOMYCIN; INTERLEUKIN 6; MICRORNA; MICRORNA LET 7A; TRISTETRAPROLIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; INTERFERON-GAMMA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESANGIAL CELLS; MICE; MICRORNAS; TRISTETRAPROLIN;

EID: 84883563863     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2013.773976     Document Type: Article

References (72)

1. Perl, A. 2010. Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity. 43: 32-47.
2. Oates, J., and G. Gilkeson. 2002. Mediators of injury in lupus nephritis. Curr Opin Rheumatol. 14: 498-503.
3. Weening, J., V. D'Agati, M. Schwartz, S. Seshan, C. Alpers, G. Appel, J. Balow, et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Amer Soc Nephrol. 15: 241-250.
4. Rottman, J. B., and C. R. Willis. 2010. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Veter Pathol. 47: 664-676.
5. Granholm, N. A., and T. Cavallo. 1990. Mechanism of localization of immune complexes in NZB/W mice with early nephritis. Autoimmunity. 8: 17-24.
6. Menè, P. 1996. Physiology and pathophysiology of the mesangial cell. Nefrologia. 16: 8-13.
7. Cove-Smith, A., and B. M. Hendry. 2008. The regulation of mesangial cell proliferation. Nephron Exper Nephrol. 108: e74-79.
8. Seret, G., Y. Le Meur, Y. Renaudineau, and P. Youinou. 2012. Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis. Clin Develop Immunol. 2012: 8 pp. Article ID 579670.
9. Peairs, A., R. Dai, L. Gan, S. Shimp, M. N. Rylander, L. Li, and C. M. Reilly. 2010. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. Cell Mol Immunol. 7: 123-132.
10. Tackey, E., P. E. Lipsky, and G. G. Illei. 2004. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 13: 339-343.
11. Eitner, F., R. Westerhuis, M. Burg, B. Weinhold, H. J. Grone, T. Ostendorf, U. Ruther, et al. 1997. Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int. 51: 69-78.
12. Saal, S., and S. J. Harvey. 2009. MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens. 18: 317-323.
13. Brooks, W. H., C. Le Dantec, J. O. Pers, P. Youinou, and Y. Renaudineau. 2010. Epigenetics and autoimmunity. J Autoimmun. 34: J207-219.
14. Sato, F., S. Tsuchiya, S. J. Meltzer, and K. Shimizu. 2011. MicroRNAs and epigenetics. FEBS J. 278: 1598-1609.
15. Asirvatham, A. J., W. J. Magner, and T. B. Tomasi. 2009. miRNA regulation of cytokine genes. Cytokine. 45: 58-69.
16. He, L., and G. J. Hannon. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nature Rev Genetics. 5: 522-531.
17. Iliopoulos, D., H. A. Hirsch, and K. Struhl. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 139: 693-706.
18. Ma, F., X. Liu, D. Li, P. Wang, N. Li, L. Lu, and X. Cao. 2010. MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolinmediated IL-10 mRNA degradation. J Immunol. 184: 6053-6059.
19. Vasudevan, S., Y. Tong, and J. A. Steitz. 2007. Switching from repression to activation: microRNAs can up-regulate translation. Science. 318: 1931-1934.
20. Meng F. H. R., H. Wehbe-Janek, H. Smith, Y. Ueno, and T. Patel. 2007. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 282: 8256-8264.
21. Dai, Y., W. Sui, H. Lan, Q. Yan, H. Huang, and Y. Huang. 2008. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 29: 749-754.
22. Divekar, A. A., S. Dubey, P. R. Gangalum, and R. R. Singh. 2011. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol. 186: 924-930.
23. Dong, Q., P. Meng, T. Wang, W. Qin, F. Wang, J. Yuan, Z. Chen, et al. 2010. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE. 5: e10147.
24. Chen, C. Y., and A. B. Shyu. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 20: 465-470.
25. Gao, M., C. J. Wilusz, S. W. Peltz, and J. Wilusz. 2001. A novel mRNA-decapping activity in HeLa cytoplasmic extracts is regulated by AU-rich elements. EMBO J. 20:1134-1143.
26. Jing, Q., S. Huang, S. Guth, T. Zarubin, A. Motoyama, J. Chen, F. Di Padova, et al. 2005. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 120: 623-634.
27. Ryan, M. J., G. R. McLemore Jr, and S. T. Hendrix. 2006. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension. 48: 988-993.
28. Peutz-Kootstra, C. J., E. de Heer, P. J. Hoedemaeker, C. K. Abrass, and J. A. Bruijn. 2001. Lupus nephritis: lessons from experimental animal models. J Labor Clin Med. 137: 244-260.
29. Burnett, R., G. Ravel, and J. Descotes. 2004. Clinical and histopathological progression of lesions in lupus-prone (NZB NZW) F1 mice. Exper Toxicol Pathol: Off J Gesellschaft fur Toxikologische Pathologie. 56: 37-44.
30. Theofilopoulos, A. N., and F. J. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv Immunol. 37: 269-390.
31. Mene, P., and A. Stoppacciaro. 2009. Isolation and propagation of glomerular mesangial cells. Meth Mol Biol. 466: 1-15.
32. Scindia, Y., U. Deshmukh, P. R. Thimmalapura, and H. Bagavant. 2008. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 58: 3884-3891.
33. Hartner A., H. Schöcklmann, F. Pröls, U. Müller, R. B. Sterzel. 1999. Alpha8 Integrin in glomerular mesangial cells and in experimental glomerulonephritis. Kidney Inter. 56: 1468-1480.
34. Dai, R., R. A. Phillips, Y. Zhang, D. Khan, O. Crasta, and S. A. Ahmed. 2008. Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood. 112: 4591-4597.
35. Coller, J. 2008. Methods to determine mRNA half-life in Saccharomyces cerevisiae. Meth Enzymol. 448: 267-284.
36. Krek, A., D. Grun, M. N. Poy, R. Wolf, L. Rosenberg, E. J. Epstein, P. MacMenamin, et al. 2005. Combinatorial microRNA target predictions. Nat Genet. 37: 495-500.
37. John, B., A. J. Enright, A. Aravin, T. Tuschl, C. Sander, and D. S. Marks. 2004. Human MicroRNA targets. PLoS Biol. 2: e363.
38. Schulte, L. N., A. Eulalio, H. J. Mollenkopf, R. Reinhardt, and J. Vogel. 2011. Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let-7 family. EMBO J. 30: 1977-1989.
39. Zhao, W., M. Liu, N. J. D'Silva, and K. L. Kirkwood. 2011. Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 30 untranslated region. J Interfer Cytokine Res Off J Inter Soc Interferon Cytokine Res. 31: 629-637.
40. Mendell, J. T. 2005. MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 4: 1179-1184.
41. Calin, G. A., and C. M. Croce. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer. 6: 857-866.
42. Lewis, B. P., C. B. Burge, and D. P. Bartel. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120: 15-20.
43. Dai, Y., Y. S. Huang, M. Tang, T. Y. Lv, C. X. Hu, Y. H. Tan, Z. M. Xu, and Y. B. Yin. 2007. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 16: 939-946.
44. Zhao, S., Y. Wang, Y. Liang, M. Zhao, H. Long, S. Ding, H. Yin, and Q. Lu. 2010. MicroRNA-126 regulates DNA methylation in CD4(\+) T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 63: 1376-1386.
45. Hai-yan, W., L. Yang, C. Mei-hong, and Z. Hui. 2011. Expression of MicroRNA-146a in peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Acta Academiae Medicinae Sinica. 33: 185-188.
46. Dalal, S. R., and J. H. Kwon. 2010. The role of MicroRNA in inflammatory bowel disease. Gastroenterol Hepatol. 6: 714-722.
47. Pauley, K. M., S. Cha, and E. K. Chan. 2009. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 32: 189-194.
48. Tufekci, K. U., M. G. Oner, S. Genc, and K. Genc. 2011. MicroRNAs and Multiple Sclerosis. Autoimmune Dis. 2011: 27 pp. Article ID 807426.
49. Rusk, N. 2008. When microRNAs activate translation. Nat Meth. 5: 122-123.
50. Vasudevan, S., Y. Tong, and J. A. Steitz. 2008. Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle. 7: 1545-1549.
51. Zhou, R., G. Hu, J. Liu, A. Y. Gong, K. M. Drescher, and X. M. Chen. 2009. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathogens. 5: e1000681.
52. Wang, D. J., A. Legesse-Miller, E. L. Johnson, and H. A. Coller. 2012. Regulation of the let-7a-3 promoter by NF-kappaB. PLoS ONE. 7: e31240.
53. Mihara, M., N. Nishimoto, and Y. Ohsugi. 2005. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 5: 683-690.
54. Asirvatham, A. J., C. J. Gregorie, Z. Hu, W. J. Magner, and T. B. Tomasi. 2008. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol Immunol. 45: 1995-2006.
55. Chege, D., Y. Chai, S. Huibner, L. McKinnon, C. Wachihi, M. Kimani,W. Jaoko, et al. 2010. Evaluation of a quantitative real-time PCR assay to measure HIV-specific mucosal CD8\+ T cell responses in the cervix. PLoS ONE. 5:e13077.
56. Collison, L. W., M. R. Pillai, V. Chaturvedi, and D. A. Vignali. 2009. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol. 182: 6121-6128.
57. Sanduja, S., V. Kaza, and D. A. Dixon. 2009. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging. 1: 803-817.
58. Al-Haj, L., P. J. Blackshear, and K. S. Khabar. 2012. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucl Acids Res. 40: 7739-7752.
59. Zhou, J. Y., W. L. Ma, S. Liang, Y. Zeng, R. Shi, H. L. Yu, W. W. Xiao, and W. L. Zheng. 2009. Analysis of microRNA expression profiles during the cell cycle in synchronized HeLa cells. BMB Rept. 42: 593-598.
60. Brennecke, J., A. Stark, R. B. Russell, and S. M. Cohen. 2005. Principles of microRNA-target recognition. PLoS Biology. 3: e85.
61. Jalonen, U., E. L. Paukkeri, and E. Moilanen. 2008. Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine j774 macrophages. J Pharmacol Exp Ther. 326: 514-522.
62. Carrick, D. M., W. S. Lai, and P. J. Blackshear. 2004. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther. 6: 248-264.
63. Taylor, G. A., E. Carballo, D. M. Lee, W. S. Lai, M. J. Thompson, D. D. Patel, D. I. Schenkman, et al. 1996. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 4: 445-454.
64. Theofilopoulos, A. N., and B. R. Lawson. 1999. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis. 58: 149-55.
65. Fahling, M., A. B. Persson, B. Klinger, E. Benko, A. Steege, M. Kasim, A. Patzak, et al. 2012. Multi-level regulation of HIF-1 signaling by TTP. Mol Biol Cell. 23: 4129-4141.
66. Kirou, K. A., C. Lee, and M. K. Crow. 2004. Measurement of cytokines in autoimmune disease. Meth Mol Med. 102: 129-154.
67. Al-Janadi, M., S. Al-Balla, A. Al-Dalaan, and S. Raziuddin. 1993. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 13: 58-67.
68. Herrera-Esparza, R., O. Barbosa-Cisneros, R. Villalobos-Hurtado, and E. Avalos-Diaz. 1998. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus. 7: 154-158.
69. Mihara, M., N. Takagi, Y. Takeda, and Y. Ohsugi. 1998. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 112: 397-402.
70. Finck, B. K., B. Chan, and D. Wofsy. 1994. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 94: 585-591.
71. Liang, B., D. B. Gardner, D. E. Griswold, P. J. Bugelski, and X. Y. Song. 2006. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 119: 296-305.
72. Polikepahad, S., J. M. Knight, A. O. Naghavi, T. Oplt, C. J. Creighton, C. Shaw, A. L. Benham, et al. 2010. Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem. 285: 30139-30149.